With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Institution	Shares	Value	Change
SUSQUEHANNA INTERNATIONAL GROUP, LLP	31,024,311	$1.1B	INCREASED
DODGE & COX	19,333,750	$711M	NEW
LOOMIS SAYLES & CO L P	17,017,315	$625M	DECREASED
FRANKLIN RESOURCES INC	16,083,479	$591M	INCREASED
Capital International Investors	11,795,850	$425M	INCREASED

Novo-Nordisk A/S (NVO) Ownership & Trading Activity

Top Institutional Holders